PTC THERAPEUTICS, INC.
StreetZero Signal 55
About PTC THERAPEUTICS, INC.
PTC Therapeutics, Inc. is a global biopharmaceutical company dedicated to the discovery, development and commercialization of clinically differentiated medicines for children and adults living with rare disorders. The company advances a robust and diversified pipeline of transformative medicines to address unmet medical needs and leverages its scientific expertise and global commercial infrastructure. It is publicly traded on NASDAQ under the ticker PTCT and reported Q3 sales of $217.13 million. Headquarters are located in Warren, NJ.
LATEST FUNDINGRule 144
$178K
Announced 2026-11-16
IN THE NEWS
- ๐ PTC Therapeutics Gets $1B Funding From Blackstone, Shares Fall
- ๐ PTC Therapeutics, Inc. Company Overview, Contact Details & Competitors | LeadIQ
- ๐ PTC Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- ๐ PTC Therapeutics, Inc.
- ๐ PTC THERAPEUTICS PRICES INITIAL PUBLIC OFFERING | PTC Therapeutics.
EMPLOYEESโ
FOUNDED1998
HQWarren, NJ, US
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyRare DiseasesPublicBiopharma
Investors
Key highlights
- Completed Rule 144 placement of $177,887.12 with undisclosed investors.
- Entered $1B strategic financing collaboration with Blackstone Life Sciences and Blackstone Credit.
- Publicly traded on NASDAQ (PTCT) since 2013 IPO.
- Focuses on rare disorder treatments with reported Q3 revenue of $217.13 million.
Ask StreetZero about PTC THERAPEUTICS, INC.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account